Navigation Links
Pharmasset to Present at the Leerink Swann Hot Topics Roundtable Conference
Date:2/14/2011

of combinations of small molecules without Pegasys® and Copegus® to treat chronic HCV. These clinical studies are being conducted through a strategic collaboration with Roche. Our other clinical stage HCV candidates include PSI-7977, an unpartnered uracil nucleotide analog that is currently dosing in two Phase 2b studies in patients with HCV genotypes 1, 2, or 3, and PSI-938, an unpartnered guanosine nucleotide analog which recently completed a 14-day monotherapy study and recently initiated a 14-day combination study with PSI-7977. We also have in our pipeline an additional purine nucleotide analog, PSI-661, in advanced preclinical development.

Pegasys(R) and Copegus(R) are registered trademarks of Roche. ContactRichard E. T. Smith, Ph.D.VP, Investor Relations and Corporate CommunicationsOffice +1 (609) 613-4181 Forward-Looking StatementsPharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995:  Statements in this press release that are not historical facts are "forward-looking statements," that involve risks, uncertainties, and other important factors, including, without limitation,  the risk of cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates,  the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful, and the risk that any one or more of our product candidates will not be successfully developed and commercialized.  For a discussion of risks, uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended September
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pharmasset Reports Fiscal First Quarter 2011 Financial Results
2. Pharmasset Announces Exercise of Underwriters Overallotment Option
3. Pharmasset Prices Public Offering of Common Stock
4. Pharmasset Announces Proposed Public Offering of Common Stock
5. Pharmasset Reports Positive Results from its HCV Clinical Programs
6. Pharmasset to Present at the 29th Annual J.P. Morgan Healthcare Conference
7. Pharmasset Initiates Exploratory Interferon Sparing Clinical Trial of PSI-7977 for Chronic Hepatitis C
8. Pharmasset to Webcast an Investor Event from the AASLD Meeting
9. Pharmasset to Present at the JMP Healthcare Conference
10. Pharmasset to Present at the UBS Global Life Sciences Conference
11. Pharmasset Initiates Phase 2b Clinical Trial of PSI-7977 for Chronic Hepatitis C Genotypes 1, 2, and 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... Children,s National Health System has announced ... 5 p.m. EDT for its "Make Your Medical ... continued strong interest from inventors.  Two ... to the winning presentations at the Sheikh Zayed Institute ... Children,s National in October. For competition details,  click ...
(Date:9/22/2014)... 2014 Decision Resources Group finds that by the ... be worth $2 billion (U.S. dollars), increasing at a compound ... years (to 2018). This growth comes as Chile ... and 4.9 percent expected over the next three to five ... but highly competitive. The pharmaceutical market is dominated by prescription ...
(Date:9/22/2014)... DIEGO , Sept. 22, 2014  Aethlon ... targeted therapeutic devices to address infectious disease, cancer ... Defense Advanced Research Projects Agency (DARPA) has informed ... option to proceed with year four of a ... Aethlon on September 30, 2011 under DARPA,s Dialysis-Like ...
Breaking Medicine Technology:Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 2Calling all medical innovators: Submit your pediatric medical device pitch for Children's National competition by Sept. 29 3Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 2Despite Its Limited Size, Chile's Pharmaceutical Market Offers Growing Opportunity for Drug Industry 3Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
(Date:9/22/2014)... September 22, 2014. Kessler researchers have published a ... psychoeducational wellness program in people with multiple sclerosis ... mental health, perceived stress, and pain. "Development ... individuals living with MS: Description and outcomes" was ... the International Journal of MS Care ...
(Date:9/22/2014)... 22, 2014 As concerns about ... power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ) in gynecological surgeries ... detailing the continued use of uterine morcellation by ... specifically discouraged these procedures. According to The Wall ... cancer risks associated with power morcellators are overblown, ...
(Date:9/22/2014)... Barbara Bronson Gray HealthDay ... It,s something every pregnant woman wonders: What can I do ... that taking iron supplements as prescribed may play a role ... spectrum disorder (ASD). The researchers found that mothers of ... iron supplements before and during pregnancy than those whose children ...
(Date:9/22/2014)... 22, 2014 In a continued effort ... Dodge Ram is launching an awareness campaign inspired by ... or #ffbBEC) aims to raise awareness and funds for ... an egg in the air and trying to catch ... and if a nominee does not complete the challenge ...
(Date:9/22/2014)... Researchers have developed a chip capable of ... the new system to test the effectiveness of ... system, called a tumor-microenvironment-on-chip (T-MOC) device, will allow ... and the barriers that prevent the targeted delivery ... University associate professor of mechanical engineering., Researchers are ...
Breaking Medicine News(10 mins):Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3Health News:Blind Egg Challenge Raises Awareness for Foundation Fighting Blindness 2Health News:New chip promising for tumor-targeting research 2
... be appointed for Scotland for coordinating efforts when an epidemic ... for giving his expert advice will be paid ?50,000 annually.// ... can mutate to spread rapidly among human beings. The exact ... revealed. The person appointed will dedicate himself solely to a ...
... created a non-invasive sensor that will help treat ... a patient faces respiratory distress in the emergency ... via a mask. But for some people with ... down the body's breathing reflex. , ,Spotting ...
... the US and Canada are looking to India to ... ,"Our consortium is trying to network to provide ... Remmers, a pioneer in the study of sleep disorder ... the consortium would include Christian Guilleminault, known as the ...
... the press that the drug Dasatinib has led to reduction ... , This drug is very effective in the ... previously used drug Gleevec. ,Chronic myeloid leukemia (CML) ... stage and the blast stage.,Dasatinib was tried on all these ...
... to enroll in treatment trials for lung cancer, according to ... of CANCER, the journal of the American Cancer Society.// ... a part of the chemotherapy regimen are primarily approved after ... well as researchers have stressed the need to enroll more ...
... Robarts Research Institute have found that supplementation of GSK-3 ... produce immune cells which fights against cancer cells.// Researchers ... in the treatment of Alzheimer’s and diabetes to boost ... effects. ,Cancer chemotherapy apart from being ...
Cached Medicine News:Health News:Cheap Indian devices sought to treat sleep disorder 2Health News:Wonder drug Dasatinib gives hopes to leukemia patients 2
... of six analyzer models providing a range of ... include pH, PCO 2 , PO 2 , ... calcium, chloride, glucose, and lactate. Test results are ... saving design provides the smallest footprint of any ...
... The modular design of Sleepscan VISION ... as economical upgrade opportunities. Sleepscan VISION utilizes ... to the computer through a standard Ethernet ... in the computer, allowing the Sleepscan VISION ...
... first 192 channel simultaneous sampling EEG with ... routine EEG exam rooms as well as ... Optional analysis software for automatic spike ... sleep analysis. Quality Data Acquisition ,The ...
... purchase an XLTEK Mobee, you're getting an ambulatory ... the Mobee32 and the Mobee O2 can be ... traditional in-lab EEG monitoring, or in-lab sleep studies. ... for full 10/20 electrode placement. The Mobee O2 ...
Medicine Products: